Inhibition of BCR Signaling Using the Syk Inhibitor TAK-659 Prevents Stroma-Mediated Signaling in Chronic Lymphocytic Leukemia Cells

dc.contributor.author
Purroy, Noelia
dc.contributor.author
Carabia, Júlia
dc.contributor.author
Abrisqueta, Pau
dc.contributor.author
Egia-Mendikute, Leire
dc.contributor.author
Aguiló, Meritxell
dc.contributor.author
Carpio, Cecilia
dc.contributor.author
Palacio, Carles
dc.contributor.author
Crespo, Marta
dc.contributor.author
Bosch, Francesc
dc.date.accessioned
2024-12-05T22:20:35Z
dc.date.available
2024-12-05T22:20:35Z
dc.date.issued
2020-12-16T11:45:15Z
dc.date.issued
2020-12-16T11:45:15Z
dc.date.issued
2017-01-03
dc.date.issued
2020-12-16T11:45:15Z
dc.identifier
https://doi.org/10.18632/oncotarget.13557
dc.identifier
1949-2553
dc.identifier
http://hdl.handle.net/10459.1/70102
dc.identifier.uri
http://hdl.handle.net/10459.1/70102
dc.description.abstract
Proliferation and survival of chronic lymphocytic leukemia (CLL) cells depend on microenvironmental signals coming from lymphoid organs. One of the key players involved in the crosstalk between CLL cells and the microenvironment is the B-cell receptor (BCR). Syk protein, a tyrosine kinase essential for BCR signaling, is therefore a rational candidate for targeted therapy in CLL. Against this background, we tested the efficacy of the highly specific Syk inhibitor TAK-659 in suppressing the favorable signaling derived from the microenvironment. To ex vivo mimic the microenvironment found in the proliferation centers, we co-cultured primary CLL cells with BM stromal cells (BMSC), CD40L and CpG ODN along with BCR stimulation. In this setting, TAK-659 inhibited the microenvironment-induced activation of Syk and downstream signaling molecules, without inhibiting the protein homologue ZAP-70 in T cells. Importantly, the pro-survival, proliferative, chemoresistant and activation effects promoted by the microenvironment were abrogated by TAK-659, which furthermore blocked CLL cell migration toward BMSC, CXCL12, and CXCL13. Combination of TAK-659 with other BCR inhibitors showed synergistic effect in inducing apoptosis, and the sequential addition of TAK-659 in ibrutinib-treated CLL cells induced significantly higher cytotoxicity. These findings provide a strong rationale for the clinical development of TAK-659 in CLL.
dc.description.abstract
This work was supported by research funding from the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI 11/00792, PI14/00055, F.B and PI13/00279, M.C), cofinanced by the European Regional Development Fund (ERDF) and Asociación Española Contra el Cáncer (AECC, M.C). N.P. is a recipient of a PhD fellowship granted by Institut de Recerca Vall d’Hebron. C.C. is supported by a grant from Sociedad Española de Hematología y Hemoterapia (SEHH). M.C. holds a contract from Ministerio de Economía y Competitividad (MINECO) (RYC-2012-12018).
dc.format
application/pdf
dc.language
eng
dc.publisher
Impact Journals
dc.relation
info:eu-repo/grantAgreement/MINECO//RYC-2012-12018/ES/RYC-2012-12018/
dc.relation
Reproducció del document publicat a: https://doi.org/10.18632/oncotarget.13557
dc.relation
Oncotarget, 2017, vol. 8, num. 1, p. 742-756
dc.rights
cc-by (c) Purroy, Noelia et al., 2017
dc.rights
info:eu-repo/semantics/openAccess
dc.rights
http://creativecommons.org/licenses/by/3.0/es
dc.subject
CLL
dc.subject
Syk
dc.subject
Microenvironment
dc.subject
TAK-659
dc.subject
BCR inhibitor
dc.title
Inhibition of BCR Signaling Using the Syk Inhibitor TAK-659 Prevents Stroma-Mediated Signaling in Chronic Lymphocytic Leukemia Cells
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)